Introduction {#sec1-1}
============

Natural products have long been a fertile source of drugs against cancer, which is projected to become the major cause of death in this century. There are at least 250000 species of plants of which, more than 1000 plants have documented anticancer properties.\[[@ref1]\] Out of 121 prescription anticancer drugs in use today, 90 are derived from plant species.\[[@ref2]\] Many herbs have been evaluated in clinical studies and are currently being investigated phytochemically to understand their tumoricidal actions against various cancers.\[[@ref3]\] Major classes of anticancer compounds include alkaloids, terpenoids, flavonoids, and lignans.\[[@ref4]\] We have chosen steroids (terpenoids) from *Asparagus racemosus* roots, because terpenoids, like taxol are currently being widely used in cancer chemotherapy.\[[@ref4]\]

The plant *Asaparagus racemosus* is reported to contain steroidal saponins as a major class along with minor steroids and their glucosides, alkaloids, flavonoids, and triterpenoids.\[[@ref5]\] The major steroidal glucosides (saponins) such as shatavarin I to X (shatavarins) were reported from the roots.\[[@ref6][@ref7]\] The total extract, polar and non-polar extracts, and their formulations exhibit immuno-pharmacological activity in cancer chemotherapy.\[[@ref8]\] The extracts of this plant also reported to produce inhibitory action on 7, 12-dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis in rats.\[[@ref9]\] Hence, in the present study, we investigated the anticancer properties of shatavarins (containing shatavain IV) from the roots of *Asparagus racemosus* (Wild).

Materials and Methods {#sec1-2}
=====================

*Asparagus racemosus* roots (AR) were collected from Tumkur district, Karnataka, India and was authenticated by Dr. Kannan, R&D Center, The Himalaya Drug Company, Bangalore, India.

 {#sec2-1}

### Extraction and Fractionation {#sec3-1}

The air-dried powdered material (7.5 kg) was subjected to repeated extraction by maceration at room temperature with various solvents of different polarity such as chloroform (20 L), chloroform:methanol (2:1) (20 L) and methanol (20 L) successively for 7 days with each solvent. Each extract was filtered, concentrated and dried at reduced pressure, and controlled temperature (40-60°C), which yielded 23 g of chloroform extract (AR-1), 437 g chloroform:methanol (2:1) extract (AR-2) and 845 g of methanol extract (AR-3). The dried extracts of AR-1 (20 g), AR-2 (400 g), and AR-3 (800 g) were again subjected to fractionation by maceration at room temperature. AR-1 was fractionated with hexane (1 L) to separate hexane soluble (AR-1A) and insoluble (AR-1B) fractions, same way AR-2 with ethyl acetate (8 L) to separate ethyl acetate soluble (AR-2A) and insoluble (AR-2B) and AR-3 with n-butanol (15 L) to separate n-butanol soluble (AR-3A) and insoluble (AR-3B) fractions. Each fraction was filtered, concentrated and dried, which yielded 19.6 g of AR-1A, negligible residue of AR-1B, 10 g of AR-2A, 375 g of AR-2B, 24 g of AR-3A, and 700 g of AR-3B.

### Identification and Estimation of Shatavarin IV/shatavarins {#sec3-2}

### High performance thin layer chromatography (HPTLC) {#sec3-3}

All the AR extracts and its fractions were subjected to identification and estimation of shatavarin IV by HPTLC \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref10]\] One gram sample was dissolved with methanol made up to 100 ml with same solvent. Shatavarin IV (B.No T9G034 (99%) from Natural Remedies) at 1 mg/ml concentration in methanol was used as standard. Ten microliter of sample and standard were spotted on CAMAG Linomat V as 12 mm band width on a precoated Silica gel 60 F~254~ plate of thickness (0.2 mm). The plate was developed in the solvent system chloroform:methanol:water 65:35:10 (lower layer). Identification of the bands of shatavarins (containing shatavarin IV) was done by dipping the plate with vanillin sulfuric acid reagent and heating at 110°C for 5 to 10 min and the concentration of shatavarin IV was estimated by scanning the plate at 640 nm.

### Isolation and characterization of shatavarin IV {#sec3-4}

As per HPTLC analysis, shatavarins rich fraction AR-2B (130 g; containing shatavrain IV-5.05 %) was further subjected to column chromatography to separate shatavarin IV on Silica gel (60-120) by elution with chloroform (0.5 L), chloroform:ethyl acetate mixture (2 L), ethyl acetate (1 L), ethyl acetate:methanol mixture (5.5 L) with increasing polarity up to methanol (1.5 L) led to separation of nine fractions designated as AR2B-F~1~ to F~9~. Major fraction (AR-2BF~7B~) was further subjected for the identification and estimation of shatavarin IV by HPTLC \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].\[[@ref10]\]

The crystalline powder AR2B-F~7B~(66 g) having shatavarin IV (5.17%) was subjected to repeated fractionation with ethyl acetate. The ethyl acetate fraction was evaporated and the residue was recrystallized with hot methanol to get white crystalline powder (3 g) which was coded as AR2B-Shat IV (shatavarin IV). The HPTLC \[[Figure 1](#F1){ref-type="fig"}\] and mass spectra of isolated compound were matched with standard.

### Cell Culture {#sec3-5}

Human breast cancer (MCF-7), human colon adeno carcinoma (HT-29), human kidney carcinoma (A-498), and Ehrlich ascites carcinoma (EAC) tumor cells were obtained from National Centre for Cell Sciences (Pune, India).

### In Vitro Cytotoxic Activity {#sec3-6}

### Preparation of sample {#sec3-7}

*Stock solution:* Since the extract AR-2, AR-2B, and fraction AR2B-F~7B~ were rich in shatavarin IV, they were also analyzed for cytotoxicity along with isolated compound AR2B-Shat IV (shatavarin IV). Samples were separately dissolved in DMSO and volume was made up with DMEM supplemented with 2% inactivated NBCS to obtain a stock solution of 5 mg/ml, sterilized by filtration and stored at -20°C. Serial working solutions were prepared from stock at concentrations of 200, 100, 50, 25, and 12.5 mg/ml with DMEM.

Stock cells of MCF-7, HT-29, and A-498 cell lines were cultured in RPMI-1640 and DMEM supplemented with 10% sheep serum, penicillin (100 IU/ml), and streptomycin (100 μg/ml) in a humidified atmosphere of 5% CO~2~ at 37°C until confluent. The cells were dissociated with 0.2 % trypsin, 0.02 % EDTA in PBS. The cytotoxicity assay was carried out by adding 0.1 ml of cell suspension containing 10 000 cells to each well of a 96 well microtitre plate and fresh medium containing different concentrations of the samples were added at 24 h after seeding. Control cells were incubated without the test item and with DMSO (maximum 0.2 %). The microtitre plates were incubated at 37°C in a humidified incubator with 5% CO~2~ for a period of 3 days. The assay was done in triplicates. Cells were observed at different time intervals during incubation in the presence of the test item. Cellular viability was determined by the standard MTT assay method.\[[@ref11]\]

### In Vivo Anticancer Activity {#sec3-8}

The ascitic antitumor studies induced by EAC tumor cells were evaluated using healthy adult Swiss albino mice weighing 20-25 g. They were obtained from the animal house facility of The Himalaya Drug Company, Bangalore. All the animals were kept under standard laboratory conditions. Animals were provided with commercial pellet diet and purified water *ad libitum*. The study protocol was approved by the Institutional Animal Ethics Committee.

Fifty-four mice were divided in to five groups. Group I containing six animals, served as normal control, for which tumor cell inoculation was not done. The remaining animals were inoculated with EAC tumor cells (1 × 10^6^ cells/mouse) intraperitoneally and divided into four groups containing 12 mice in each group. Group II, served as the tumor control. Groups I and II received an oral dose of 10 ml/kg b.wt. sodium CMC suspension (0.3%). Group III, served as a reference drug, which was treated orally with 20 mg/kg b.wt of 5-flurouracil (5-FU). Groups IV and V were treated with AR-2B fraction at 250 and 500 mg/kg b.wt., respectively. All the treatments were given orally at 24 h after tumor inoculation and continued once daily for 10 days. On the 11th day, six animals from each group were anesthetized and blood was collected by retro-orbital puncture for evaluation of hematological parameters, which included hemoglobin (Hb), red blood cell count (RBC), white blood cell count (WBC), and absolute count. The remaining animals in each of the groups were kept to check the mean survival time (MST) and percent increase in life span (% ILS) of the tumor bearing hosts.\[[@ref12]\]

*Tumor growth response:* Antitumor effect of AR-2B was assessed by observation of change in body weight, ascitic tumor volume, packed cell volume, and viable tumor cell count, MST and % ILS.

### Tumor Cell Count and Packed Cell Volume {#sec3-9}

The mice were dissected for collecting ascitic fluid from peritoneal cavity. The transplantable murine tumor was carefully collected with the help of sterile syringe to measure the tumor volume and the ascitic fluid was transferred to a graduated glass centrifuge tube and packed cell volume was determined by centrifuging at 100 g for 5 min. Viable and non-viable cell counting of ascitic cells were performed by trypan blue stain dye exclusion test (0.4% in normal saline). The cell counts were determined in a Neubauer counting chamber. The experiment was done in triplicates and mean count was taken.

MST and % ILS: The effect of AR-2B on tumor growth was observed by MST and %ILS. MST of each group containing six mice were monitored by recording the mortality daily for 6 weeks and % ILS was calculated by using the following equation.\[[@ref13]--[@ref16]\]

![](IJPharm-44-732-g001.jpg)

### Statistical Analysis {#sec3-10}

The results are expressed as mean ± S.E.M. Data were analyzed using ANOVA followed by Dunnett\'s multiple comparison post hoc test. The CTC~50~ concentrations were calculated using linear regression analysis. The statistical analysis was performed using GraphPad Prism software (version 4.03).

Results {#sec1-3}
=======

Out of all extracts and fractions, only AR-2 (4.18%) and AR-2B (5.05 %) contained high concentrations of shatavarin IV \[[Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\] and remaining samples had negligible content of shatavarin IV. According to the HPTLC \[[Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\], the AR2B-F~7B~ fraction was rich in shatavarin IV. It was subjected to fractionation and crystallization until a single spot was obtained on HPTLC. The purified compound yielded 3 g of AR2B-Shat IV (shatavarin IV (84.89%)). The HPTLC \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\] and mass spectra of isolated AR2B-Shat IV was an exact match to the standard shatavarin IV \[[Figure 3](#F3){ref-type="fig"}\].

![Identification of shatavarins (Steroidal saponins) in different extracts (AR-1, AR-2, AR-3 and fractions (AR-2B, AR2B-F7B, AR-3 AR-3A AR-3B, AR2B-Shat IV, Shatavarin IV)](IJPharm-44-732-g002){#F1}

###### 

Comparative analysis of Shatavarin IV in different extract and fractions
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![Estimation of shatavarin IV (shatavarins) in different extracts (AR-1, AR-2, AR-3) and fractions (AR-2B, AR2B-F~7B~, AR-3 AR-3A AR-3B, AR2B-Shat IV)](IJPharm-44-732-g004){#F2}

![Structure of Shatavarin IV](IJPharm-44-732-g005){#F3}

 {#sec2-2}

### In Vitro Cytotoxic Activity {#sec3-11}

AR-2 and AR-2B fractions were subjected to cytotoxicity along with separated fraction AR2B-F~7B~ and isolated compound AR2B-Shat-IV (shatavarin IV). The results of CTC~50~ and % cytotoxicity of AR-2, AR-2B, AR2B-F~7B~, and AR2B-Shat-IV are shown in Figures [4a](#F4){ref-type="fig"}, [b](#F4){ref-type="fig"}. The AR-2B, AR2B-F~7B~, and AR2B-Shat IV exhibited potent cytotoxicity on the MCF-7, HT-29, and A-498 cell lines.

![(a and b) *In vitro* cytotoxicity of AR-2, AR-2B, AR2B-F~7B~ and AR2B-Shat IV](IJPharm-44-732-g006){#F4}

### In Vivo Anticancer Activity {#sec3-12}

### Effect on tumor growth {#sec3-13}

In the EAC tumor control group, the average life span of animals was found to be 21.45±1.58 days. AR-2B at doses of 250 and 500 mg/kg b.wt. showed a significant change in the average life span as compared to EAC control. The average life span of 5-FU treatment was found to be 27.48±1.40 days \[[Figure 5](#F5){ref-type="fig"}\]. A dose dependent antitumor action of AR-2B was observed as a significant reduction in body weight, reduction in tumor volume, packed cell volume and viable tumor cell count, and increase in non-viable tumor cell count in both doses as compared to the EAC tumor control \[[Table 2](#T2){ref-type="table"}\].

![Effect of AR-2B extracts of *Asparagus racemosus* on survival time of EAC baring mice. Values are Mean ± SEM, No. of mice in each group: 6; ^a^*P* \< 0.05, ^b^*P* \< 0.01 as compared with EAC control](IJPharm-44-732-g007){#F5}

###### 

Effect of AR-2B fraction of *Asparagus racemosus* on tumor volume, packed cell volume, viable, and non-viable tumor cell count on EAC bearing mice
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### Effect of hematological parameters {#sec3-14}

EAC tumor bearing mice showed a significant decrease in RBC count, hemoglobin, and a significant increase in WBC count as compared to normal control. There was also a significant increase in the lymphocyte count with an increase in neutrophil (granulocyte) counts in EAC tumor bearing mice as compared to normal control. Treatment with AR-2B significantly reversed EAC tumor-induced changes in hematological profiles \[[Table 3](#T3){ref-type="table"}\]. Similar observations were observed with 5-FU (Reference Drug).

###### 

Effect of AR-2B fraction *Asparagus racemosus* on hematological parameters of EAC bearing mice
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Discussion {#sec1-4}
==========

Natural products have been regarded as an important source that could contribute to potential chemotherapeutic agents. In particular, plant derived compounds have gained importance in anticancer therapy and some of the new chemotherapeutic agents currently available for use includes paclitaxel, vincristine, podophyllotoxin, and camptothecin.\[[@ref12]\] The present investigation was carried out to evaluate the anticancer activity of major shatavarins (shatavarin IV) from AR-2B fraction of *Asparagus racemosus* roots. *In vitro* cytotoxicity study using MCF-7, HT-29, and A-498 cell lines showed potent activity with AR-2B (5.05% shatavarin IV) as well as its isolated compound AR2B-shat IV (shatavarin IV). These observations provided a basis for conducting the *in vivo* study of AR-2B using EAC tumor in mice.

The reliable criteria for judging the potency of an anticancer drug is prolongation of the life span of tumor bearing animals. There is also a significant increase in body weight in EAC tumor bearing mice due to the rapid increase in the ascitic tumor volume.\[[@ref17]\] The mice bearing EAC tumor when orally administered with AR-2B showed a significant increase in the life span and a significant decrease in body weight. Treatment with AR-2B also showed a significant decrease in the tumor volume, packed cell volume, and viable tumor cell count, thereby indicating the anticancer nature of AR-2B. These results indicate either a direct cytotoxic effect on the tumor cells or local cytotoxic effect of AR-2B.

The major drawback of cancer chemotherapy encountered are myelosuppression and anemia.\[[@ref18][@ref19]\] The anemia encountered in the tumor bearing mice is due to the reduction in the RBC count or hemoglobin percentage and this may occur due to iron deficiency or due to hemolytic or myelopathic conditions. Treatment with AR-2B restored the hematological profiles in our study.

Excessive production of free radical causes oxidative stress, which leads to damage of macromolecules such as lipids and can induce lipid peroxidation *in vivo*. Increased peroxidation would cause degeneration of tissues. Lipid peroxide formed in the primary site would be transferred through the circulation and cause damage by propagating the process of lipid peroxidation. Malondialdehyde (MDA), the end product of lipid peroxidation was reported to be higher in cancer tissues than in non-diseased organs. Since *Asparagus racemosus* root induced elevation of antioxidant activity could be responsible for anticancer activity.\[[@ref20]--[@ref22]\] From the above findings it could be concluded that shatavarins (containing shatavarin IV) rich fraction AR-2B (containing 5.05% shatavarin IV) from *Asparagus racemosus* roots exhibited potent anticancer activity as demonstrated by *in vitro* cytotoxicity using MCF-7, HT-29, and A-498 cell lines as well as EAC induced tumor in mice.
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